[
  {
    "ts": null,
    "headline": "Market Awaits January Manufacturing Numbers",
    "summary": "Market Awaits January Manufacturing Numbers.",
    "url": "https://finnhub.io/api/news?id=eb4169eae1051f11a4ac5c43bcde5a5a3934fd0dcd63bb08342cadf86a4b4ed1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770048720,
      "headline": "Market Awaits January Manufacturing Numbers",
      "id": 138333980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Market Awaits January Manufacturing Numbers.",
      "url": "https://finnhub.io/api/news?id=eb4169eae1051f11a4ac5c43bcde5a5a3934fd0dcd63bb08342cadf86a4b4ed1"
    }
  },
  {
    "ts": null,
    "headline": "Six More Weeks of Q4 Earnings Season?",
    "summary": "We're quiet to start a new trading week, but this is both Jobs Week and the busiest Q4 earnings week thus far.",
    "url": "https://finnhub.io/api/news?id=75c490e073137a7621df073f470432a31ad27c922d63f02245912cd99f3efd1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770046500,
      "headline": "Six More Weeks of Q4 Earnings Season?",
      "id": 138333683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We're quiet to start a new trading week, but this is both Jobs Week and the busiest Q4 earnings week thus far.",
      "url": "https://finnhub.io/api/news?id=75c490e073137a7621df073f470432a31ad27c922d63f02245912cd99f3efd1e"
    }
  },
  {
    "ts": null,
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
    "url": "https://finnhub.io/api/news?id=80649950b33082b20364be17e694b012330a1b2a8b254d291dc2e8103f26dbe0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770045900,
      "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
      "id": 138333684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.",
      "url": "https://finnhub.io/api/news?id=80649950b33082b20364be17e694b012330a1b2a8b254d291dc2e8103f26dbe0"
    }
  },
  {
    "ts": null,
    "headline": "iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release",
    "summary": "iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=6b5e61b01551bfee9c3b6a250b02b38dba058b33e5845c7982e39aceee323df3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770044405,
      "headline": "iBio, Inc. (IBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release",
      "id": 138333819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "iBio (IBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=6b5e61b01551bfee9c3b6a250b02b38dba058b33e5845c7982e39aceee323df3"
    }
  },
  {
    "ts": null,
    "headline": "Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007",
    "summary": "We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifth stock on our list of best biotech stocks is Janux Therapeutics, Inc. TheFly reported on January 20 that Clear Street downgraded JANX to Hold from Buy and lowered the price target to $12 from $32. The firm […]",
    "url": "https://finnhub.io/api/news?id=eded99215ad2d1b25cb5303c6098ea42ddabb1364d77e6e9c6dee64d4a486a73",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770043006,
      "headline": "Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007",
      "id": 138332537,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The fifth stock on our list of best biotech stocks is Janux Therapeutics, Inc. TheFly reported on January 20 that Clear Street downgraded JANX to Hold from Buy and lowered the price target to $12 from $32. The firm […]",
      "url": "https://finnhub.io/api/news?id=eded99215ad2d1b25cb5303c6098ea42ddabb1364d77e6e9c6dee64d4a486a73"
    }
  },
  {
    "ts": null,
    "headline": "Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics",
    "summary": "Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
    "url": "https://finnhub.io/api/news?id=c1ef5838d4dbc1118fae657d7ed8986ce7c1e7e3fcfa846cab8cfa5a19f9edf2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770041704,
      "headline": "Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics",
      "id": 138333820,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
      "url": "https://finnhub.io/api/news?id=c1ef5838d4dbc1118fae657d7ed8986ce7c1e7e3fcfa846cab8cfa5a19f9edf2"
    }
  },
  {
    "ts": null,
    "headline": "Lupin Launches Dasatinib Tablets in the United States",
    "summary": "Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. The product was developed in partnership with Pharmascience Inc.",
    "url": "https://finnhub.io/api/news?id=135963dd0e826c26d869f3b039be7811dbc4672e28b4cf891aec61843a642178",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770039000,
      "headline": "Lupin Launches Dasatinib Tablets in the United States",
      "id": 138331717,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Dasatinib Tablets, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. The product was developed in partnership with Pharmascience Inc.",
      "url": "https://finnhub.io/api/news?id=135963dd0e826c26d869f3b039be7811dbc4672e28b4cf891aec61843a642178"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?",
    "summary": "BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.",
    "url": "https://finnhub.io/api/news?id=dec307c30b2f6d8fa45451eccf4699b663ae9611b572873ab016e892d146b92f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770037800,
      "headline": "Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?",
      "id": 138332523,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.",
      "url": "https://finnhub.io/api/news?id=dec307c30b2f6d8fa45451eccf4699b663ae9611b572873ab016e892d146b92f"
    }
  }
]